- Americans with IDD face enormous obstacles when seeking quality health services
- The vast majority of Americans with IDD are enrolled in state Medicaid programs. MCOs struggle with the IDD population because they’re statistical outliers, physicians and dentists aren’t trained to care for them, the population is not properly risk-adjusted, and frequently, MCOs treat them all the same
- For all these reasons, according to the CDC, patients with IDD comprise approximately 4.9% of Medicaid enrollees, but they drive 15.7% of the costs
- The transdisciplinary clinic model can significantly improve health outcomes while, at the same time, achieve major cost savings for third party payers
- Integration of data sets
- Evaluating impact of physical and mental health and social drivers of health
- Measuring outcomes for member populations
Renato Alves
Project Advisor
Pelago Bioscience
Thomas Geiger
Scientist
TU Darmstadt
Katelyn Cassidy
UPS Biology, Proteomics Scientist
C4 Therapeutics
Ingrid Wertz
CEO & Co-Founder
Lyterian Therapeutics
Clone of Ingrid Wertz
Executive Director, Protein Homeostasis Center of Excellence
BMS
Ingrid E. Wertz is the Executive Director of the Protein Homeostasis Center of Excellence at Bristol Myers Squibb. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Dr. Wertz was a recipient of the Harold M. Weintraub Graduate Student Award. Prior to joining BMS in May of 2021, Dr. Wertz was a Principal Scientist at Genentech. There she served as the Biology Lead for BCL-2 family antagonists that contributed to venetoclax, she was the initial Biology Lead for the selective estrogen receptor degrader (SERDs) program that contributed to giredistrant, she led USP7 inhibitor drug discovery teams, and co-initiated and led the Genentech Degrader Platform. Dr. Wertz’s research is primarily focused on elucidating the molecular mechanisms of therapeutic compounds and co-opting the Ubiquitin System for therapeutic benefit.
Steven Edenson
Strategic Collaborations Manager
Promega
Caroline Rynn
DMPK-PD Project Leader, Senior Principal Scientist
Roche